PMID- 25897968
OWN - NLM
STAT- MEDLINE
DCOM- 20160412
LR  - 20231104
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 4
DP  - 2015
TI  - Effects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: 
      a meta-analysis of randomized controlled trials.
PG  - e0123703
LID - 10.1371/journal.pone.0123703 [doi]
LID - e0123703
AB  - BACKGROUND: Inflammation is a common feature in patients with type 2 diabetes 
      mellitus (T2DM). This meta-analysis aimed to assess the influence of 
      thiazolidinedione (TZD) therapy on the circulating levels of inflammatory markers 
      in patients with T2DM. METHODS AND RESULTS: We searched the databases Medline, 
      Embase, ScienceDirect, Web of Science, SpringerLink, and the Cochrane Library for 
      randomized controlled trials (RCTs) that examined the effects of 
      thiazolidinedione vs. a placebo on patients with T2DM. The main outcomes were 
      absolute changes in levels of circulating inflammatory markers. Twenty-seven RCTs 
      were included and data were analyzed using a fixed-effect model or a 
      random-effect model based on heterogeneity. Pooled results indicated that 
      circulating levels of high-sensitivity C reactive protein (hsCRP; SMD = -0.65, 
      95% CI = -0.98 to -0.32, p < 0.01), monocyte chemoattractant protein-1 (MCP-1; 
      WMD = -54.19, 95% CI = -73.86 to -34.52, p < 0.01), von Willebrand factor% (vWF%; 
      WMD = -8.18, 95% CI = -13.54 to -2.81, p 0.01), fibrinogen (SMD = -0.26, 95% CI = 
      -0.41 to -0.11, p < 0.01) and E-selectin(WMD = -3.57, 95% CI = -5.59 to -1.54, p 
      <0.01) were significantly decreased after TZD therapy. However, interleukin-6 
      (IL-6), matrix metalloproteinase-9 (MMP-9), soluble CD40 ligand, plasminogen 
      activator inhibitor 1 (PAI-1) and intercellular adhesion molecule (ICAM-1) were 
      not significantly affected. Subgroup analyses of PAI-1, vWF% and fibrinogen in 
      terms of trial drugs showed significant reductions for rosiglitazone (all p 
      valuses< 0.05), but not pioglitazone treatment. Conversely, the E-selectin (p < 
      0.01) lowering effect only existed in the pioglitazone group. Further, 
      rosiglitazone and pioglitazone treatment reduced serum hsCRP and MCP-1 but had no 
      marked effects on MMP-9, IL-6 and ICAM-1. CONCLUSIONS: Limited evidence suggested 
      that TZD therapy had anti-inflammatory property that might contribute to its 
      beneficial effect on inflammatory state in patients with type 2 diabetes.
FAU - Chen, Rui
AU  - Chen R
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu Province, China.
FAU - Yan, Jinchuan
AU  - Yan J
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu Province, China.
FAU - Liu, Peijing
AU  - Liu P
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu Province, China.
FAU - Wang, Zhongqun
AU  - Wang Z
AD  - Department of Cardiology, Affiliated Hospital of Jiangsu University, Zhenjiang, 
      Jiangsu Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20150421
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Thiazolidinediones)
RN  - AA68LXK93C (2,4-thiazolidinedione)
SB  - IM
MH  - Biomarkers/blood
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/immunology
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Inflammation Mediators/*blood
MH  - Randomized Controlled Trials as Topic
MH  - Thiazolidinediones/pharmacology/*therapeutic use
MH  - Treatment Outcome
PMC - PMC4405205
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/04/22 06:00
MHDA- 2016/04/14 06:00
PMCR- 2015/04/21
CRDT- 2015/04/22 06:00
PHST- 2014/02/20 00:00 [received]
PHST- 2015/03/06 00:00 [accepted]
PHST- 2015/04/22 06:00 [entrez]
PHST- 2015/04/22 06:00 [pubmed]
PHST- 2016/04/14 06:00 [medline]
PHST- 2015/04/21 00:00 [pmc-release]
AID - PONE-D-13-53185 [pii]
AID - 10.1371/journal.pone.0123703 [doi]
PST - epublish
SO  - PLoS One. 2015 Apr 21;10(4):e0123703. doi: 10.1371/journal.pone.0123703. 
      eCollection 2015.